Developers can use the Zika virus samples to ascertain whether their tests can help distinguish Zika infection from similar diseases.
The PCR-based test can simultaneously detect for the Zika virus, all serotypes of the dengue virus, the chikungunya virus, the West Nile virus, and a host gene.
For the three months ended June 30, the point-of-care infectious disease diagnostics firm posted $4.1 million in total revenues, up from $3.3 million in Q2 2016.
The company expects to use its centrifugal microfluidic platform to launch a dengue assay early in 2018 and a Zika-dengue assay later in 2018.
The test will leverage Chembio's DPP technology platform to detect multiple diseases simultaneously.
The method uses graphene-coated silica particles fused to complementary RNA to register impedance changes in the presence of viruses.
The test addresses a major challenge of using an immunoassay for diagnosing Zika — the inability to differentiate it from other flaviviruses.
The firms also plan to launch a multiplex test for multiple pathogens, including dengue.
The kit is a qualitative nucleic acid assay designed to test for Zika, dengue, and chikungunya viruses simultaneously.
The deal gives Bio-Rad licensing rights to a PCR-based platform and an assay that improves diagnostic sensitivity and efficacy across four dengue serotypes.